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Abstract
Genome-wide association studies (GWAS) have successfully identified common genetic variants that contribute to breast
cancer risk. Discovering additional variants has become difficult, as power to detect variants of weaker effect with present
sample sizes is limited. An alternative approach is to look for variants associated with quantitative traits that in turn affect
disease risk. As exposure to high circulating estradiol and testosterone, and low sex hormone-binding globulin (SHBG) levels
is implicated in breast cancer etiology, we conducted GWAS analyses of plasma estradiol, testosterone, and SHBG to identify
new susceptibility alleles. Cancer Genetic Markers of Susceptibility (CGEMS) data from the Nurses’ Health Study (NHS), and
Sisters in Breast Cancer Screening data were used to carry out primary meta-analyses among ,1600 postmenopausal
women who were not taking postmenopausal hormones at blood draw. We observed a genome-wide significant
association between SHBG levels and rs727428 (joint b=-0.126; joint P=2.09610
–16), downstream of the SHBG gene. No
genome-wide significant associations were observed with estradiol or testosterone levels. Among variants that were
suggestively associated with estradiol (P,10
–5), several were located at the CYP19A1 gene locus. Overall results were similar
in secondary meta-analyses that included ,900 NHS current postmenopausal hormone users. No variant associated with
estradiol, testosterone, or SHBG at P,10
–5 was associated with postmenopausal breast cancer risk among CGEMS
participants. Our results suggest that the small magnitude of difference in hormone levels associated with common genetic
variants is likely insufficient to detectably contribute to breast cancer risk.
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Introduction
A family history of breast cancer is one of the strongest known
risk factors for the disease, with ,2-fold increased risk in first
degree relatives of cases [1]. Twin studies suggest that around a
quarter of the variance in breast cancer risk is due to inherited
genetic factors [2]. The BRCA1 and BRCA2 genes are both
associated with high risks of breast and ovarian cancer. However,
these mutations are rare, accounting for only 2–4% of all breast
cancers in non-founder populations [3] and about 20% of excess
familial risk [4]. Among non-BRCA mutation carriers, genetic
susceptibility to breast cancer follows a polygenic model where a
large number of variants each confer a small effect on risk [5].
Within the last 5 years, the agnostic approach of using genome-
wide association studies (GWAS) has successfully identified several
additional genetic risk variants. Together, the newly identified
alleles account for 7–8% of variation in familial risk [6], suggesting
that further variants exist. As yet unidentified variants will likely
have frequencies and/or effect sizes such that they will be hard to
detect by GWAS using sample sizes that are presently realistic.
One alternative approach is to improve power by looking for
variants associated with quantitative traits that in turn affect
disease risk.
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       Sex steroid hormones play a primary role in postmenopausal
breast cancer etiology [7]. Endogenous and exogenous character-
istics that modify exposure to steroid hormones are among the
established risk factors for breast cancer development, including
reproductive history prior to menopause [8], adiposity after
menopause [9], oral contraceptive use [10] and post-menopausal
hormone replacement therapy [11]. Additionally, direct measure-
ment of circulating hormone levels of estradiol and testosterone
[12] have shown higher levels to be strongly and consistently
associated with increased breast cancer risk. Conversely, risk may
be inversely related to plasma levels of sex hormone-binding
globulin (SHBG) [13–15], the major sex steroid transport protein
that binds estradiol and testosterone with high affinity, which may
limit their bioavailability.
Evidence of heritability has been observed for plasma levels of
estradiol, testosterone, and SHBG. Family and twin studies among
women estimate genetic factors contribute between 0–45% of
variation in log estradiol levels [16], 12–66% of variation in log
testosterone levels [16,17], and 29–83% of variation in log SHBG
levels [16,17]. Well-established associations exist between variants
within the SHBG gene (Gene ID: 6462) and circulating SHBG
levels [18–24] and between CYP19A1 variants and levels of
estradiol in post-menopausal women [20,22,25], while two
variants within the SHBG gene region and an X chromosome
SNP have recently been reported to be associated with testoster-
one concentrations in men [24]. Even so, a comprehensive
assessment of common variants within known sex steroid hormone
synthesis and metabolism pathway genes (i.e. CYP17A1, Gene ID:
1586; CYP19A1, Gene ID: 1588) found no significant associations
with breast cancer risk [26]. Given that genes regulating these
complex hormonal pathways are not fully understood or
described, variants in genes that are not yet characterized and/
or hypothesized to influence hormone synthesis and metabolism a
priori may be associated with sex hormone levels and thus breast
cancer risk.
To describe such novel genotype-phenotype associations we
conducted a GWAS of postmenopausal estradiol, testosterone, and
SHBG plasma levels. Our study included a subset of women from
the National Cancer Institute Cancer Genetic Markers of
Susceptibility (CGEMS) project and the GWAS carried out in
the framework of the Sisters in Breast Screening (SIBS) study for
whom circulating steroid hormones had been measured. Identi-
fying genetic determinants of hormonal levels may provide new
insights into breast cancer etiology.
Results
Characteristics of each study population are shown in Table 1.
All NHS and SIBS study participants were postmenopausal at the
time of blood collection. Among women who were not on PMH at
time of blood draw, a greater percentage of NHS participants had
never used PMH compared to women in the SIBS study. On
average, SIBS participants were slightly older and had a greater
BMI at blood draw compared to women in the NHS. Mean
testosterone and SHBG levels were very similar between SIBS
participants and NHS non-PMH users, although mean estradiol
levels were lower among the SIBS women. It is known that
measurements of hormone concentrations are prone to substantial
variability between different laboratories, because of the different
assays used [13]. NHS PMH users had ,3-fold higher mean
estradiol levels and ,2-fold higher mean SHBG levels compared
to NHS women who were not on PMH. Mean testosterone levels
were comparable between the PMH and non-PMH groups. No
evidence of systematic bias was observed in the GWAS meta-
analyses of the three hormones (genomic inflation factor l #1.02
for each; Figures S1, S2, S3).
Sex Hormone-binding Globulin
Genome-wide significant SNPs (P,5610
–8) associated with
SHBG levels were observed on chromosome 17 (Table 2, Figure
S4). The most significant association with SHBG levels was
observed for rs727428, which resides ,1.1 kb from the 39 end of
the SHBG gene, in both the NHS non-PMH user (P=4.08610
–8)
and SIBS (P=8.27610
–10) study populations (Table S1). The
joint P-value for the association between rs727428 and SHBG
levels was P=2.09610
–16. Effect estimates did not display
between-study heterogeneity (Pheterogeneity=0.59; Table 2). Six-
teen additional SNPs that span ,110 kb across the region on
chromosome 17p13 that includes the SHBG gene reached
genome-wide significance (P#1.93610
–8). No significant be-
Table 1. Select characteristics of study populations.
Nurses’ Health Study Sisters in Breast Screening Study
Non-PMH users
(N=804)
PMH users
(N=899) (N=819)
Never PMH use 64% – 51%
Past PMH use 36% – 49%
Mean age (SD) 61.4 (4.8) 59.9 (5.4) 62.1 (5.4)
Mean age at menopause (SD) 49.9 (4.0) 48.8 (5.0) 48.9 (5.8)
Mean BMI (kg/m
2; SD) 26.4 (5.0) 24.7 (4.2) 27.3 (5.3)
E2 measurements (N) 779 668 804
Mean E2 (pmol/L; SD)
a 29.2 (19.6) 87.1 (79.1) 20.3 (22.9)
T measurements (N) 770 875 819
Mean T (nmol/L; SD)
a 0.82 (0.5) 0.85 (0.5) 0.82 (0.5)
SHBG measurements (N) 779 898 819
Mean SHBG (nmol/L; SD) 55.1 (29.0) 112.5 (66.2) 55.0 (26.2)
aCorresponding mean E2 concentrations in pg/ml are 8.0, 23.7, and 5.5 and mean T concentrations in ng/dl are 23.7, 24.5, and 23.7 for NHS non-PMH users, NHS PMH
users, and SIBS participants, respectively.
doi:10.1371/journal.pone.0037815.t001
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ogeneity$0.19; Table S1). No SNP achieved genome-wide
significance among the group of NHS women who were on
PMH at the time of blood draw (P$1.07610
–6). Weaker effect
estimates for SNP associations with SHBG levels were observed at
the SHBG locus among PMH users, resulting in some moderate
between-study heterogeneity in secondary meta-analyses of the 3
groups (I
2#66%, Pheterogeneity$0.05; Table S2).
Estradiol
No SNP association with estradiol levels reached the nominal
genome-wide significance threshold of P=5610
–8 in the meta-
analysis of the NHS non-PMH users and SIBS participants
(Table 2, Figure S5). The SNP most significantly associated with
estradiol levels (rs6016142, P=6.47610
–8), located on chromo-
some 20q12, is ,632 kb downstream of the nearest gene: DEAH
(Asp-Glu-Ala-His) box polypeptide 35 (DHX35, Gene ID: 60625).
Suggestive associations were also observed for 34 SNPs in the
region containing the cytochrome P450, family 19, subfamily A,
polypeptide 1 (CYP19A1) gene on chromosome 15q21.1 (smallest
joint P=5.11610
–7 for rs727479; Tables 2 and S3), including
variants which were previously shown to be associated with
estradiol levels [20,22,25]. Between-study heterogeneity in effect
estimates ranged from very low to high (I
2=0% for rs17703883 to
I
2=79% for rs2899472, Pheterogeneity .0.03) for suggestive SNPs at
this locus. Genome-wide significance was not observed for any
SNP association with estradiol levels among NHS women who
were on PMH at blood draw (P$4.85610
–7). In a secondary
meta-analysis including all three groups of women, rs727479 at the
CYP19A1 locus displayed the most significant association with
estradiol levels (joint P=3.33610
–7,I
2=4%, Pheterogeneity=0.35;
Table S4).
Testosterone
No SNP association with testosterone levels reached genome-
wide significance in the meta-analysis of NHS non-PMH users and
SIBS study participants (Tables 2 and S5, Figure S6). The
most significant association with testosterone levels was observed
for rs909814 on chromosome 1p36.12. The SNP is located ,104
kb upstream of the nearest gene: wingless-type MMTV integration
site family, member 4 (WNT4, Gene ID: 54361). Among the
suggestive SNPs, an association was found in a region containing
Table 2. Summary of regions associated with log SHBG, log estradiol, and log testosterone levels at P,10
25 from GWAS meta-
analyses. of non-PMH users.
Hormone Region
a
no.
snps
span
(kB)
min-max
position (bp)
a best SNP alleles
b MAF
c b
d P-value
d Pheterogeneity
d
Genes within
20kb of best
SNP
a
SHBG 17p13 29 261 7259120–7520197 rs727428 C/T 0.42 -0.126 2.09E-16 0.59 FXR2/SHBG/SAT2/
ATP1B2
SHBG 5q14 4 75 89070647–89145506 rs10514317 C/T 0.12 -0.132 6.96E-07 0.13
SHBG 2q37 1 - 241732719 rs6721345 G/A 0.01 1.130 2.60E-06 0.35 SNED1/MTERFD2
SHBG 1q23 2 3 160688161–160690928rs424950 G/C 0.48 0.076 4.76E-06 0.43
SHBG 17q23 9 18 53163063–53181345 rs8077059 T/C 0.25 -0.081 5.40E-06 0.45
SHBG 3p12 1 - 76566873 rs3849491 C/T 0.48 -0.073 5.52E-06 0.93
SHBG 10p15 5 5 4135640–4141121 rs10795130 T/G 0.13 0.103 6.97E-06 0.48
SHBG 16q12 1 - 52585472 rs12596210 T/C 0.12 -0.120 8.74E-06 0.48 FTO
estradiol 20q12 11 127 37725829–37853256 rs6016142 C/T 0.11 -0.179 6.47E-08 0.23
estradiol 15q21 34 66 49285831–49351633 rs727479 A/C 0.34 -0.107 5.11E-07 0.25 CYP19A1/
MIR4713
estradiol 2p23 11 28 31373046–31401477 rs597800 G/C 0.15 -0.148 5.29E-07 0.84 EHD3
estradiol 7p15 8 94 29788672–29882593 rs10488084 A/C 0.08 0.180 2.37E-06 0.76 FKBP14/PLEKHA8
estradiol 11q12 1 - 61468707 rs2727261 C/T 0.09 0.159 3.27E-06 0.73 BEST1/FTH1
estradiol 19q12 2 17 36585958–36602969 rs11880316 C/A 0.01 0.414 3.63E-06 0.73
estradiol 18q22 1 - 70916034 rs17056274 A/G 0.01 0.658 3.66E-06 0.63 ZNF407
estradiol 3p26 2 3 1595644–1598393 rs402675 T/A 0.50 -0.097 6.27E-06 0.23
estradiol 6q16 3 3 96524696–96528092 rs815653 G/T 0.05 0.210 9.69E-06 0.06
estradiol 1q41 1 - 213021343 rs10495024 T/C 0.36 -0.096 9.83E-06 0.83
estradiol 1q42 1 - 231200737 rs17829302 G/T 0.08 0.215 9.94E-06 0.43
testosterone 1p36 7 9 22314053–22323369 rs909814 C/T 0.39 0.103 9.06E-07 0.44
testosterone 4q35 1 - 191016319 rs11132733 C/T 0.17 -0.225 3.31E-06 0.59
testosterone 17p12 4 1 12576879–12578327 rs9905820 T/G 0.42 -0.094 3.80E-06 0.41 MYOCD
testosterone 1q41 1 - 213021343 rs10495024 T/C 0.36 -0.103 5.59E-06 0.67
testosterone 1p33 2 1015 46996943–48011680 rs12059860 T/C 0.01 0.619 8.25E-06 0.46 CYP4B1
Testosterone20p13 1 - 4164864 rs4815670 G/A 0.44 -0.102 9.79E-06 0.13 ADRA1D
aFrom NCI genome build 35.
bMajor/minor allele.
cMinor allele frequency.
dCombined effect sizes and P values are calculated using a fixed-effects meta-analysis (METAL software).
doi:10.1371/journal.pone.0037815.t002
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(CYP4B1, Gene ID: 1580, rs12059860; joint P=8.25x10
–6,
Pheterogeneity=0.46) gene, a member of the superfamily involved
in drug and steroid hormone metabolism. Additionally, the C
allele of rs10495024, located ,44 kb downstream of the estrogen-
related receptor gamma (ESRRG, Gene ID: 2104) gene, was
associated with lower levels of both estradiol (b=20.096, joint
P=9.83610
–6) and testosterone (b=20.103, joint P=5.59610
–6;
Table 2). In contrast to the SHBG and estradiol meta-analyses,
none of the suggestive SNPs from the primary meta-analysis had
suggestive associations with testosterone levels in the secondary
meta-analysis that included the NHS PMH user group. The most
significant SNP association in the meta-analysis including all three
groups was observed for rs3218501, which lies within intron 2 of
the X-ray repair complementing defective repair in Chinese
hamster cells 2 (XRCC2, Gene ID: 7516) gene on chromosome
7q36.1 (joint P=4.49610
–7; Table S6).
Discussion
Known common genetic variants explain a small percentage of
inherited breast cancer risk and identifying additional risk loci has
become increasingly difficult [27]. Since a relatively high
cumulative lifetime exposure to sex steroid activity is known to
increase breast cancer risk, our approach was to identify novel
variants through associations with plasma levels of estradiol,
testosterone, and SHBG in two well-characterized, homogeneous
GWAS populations of postmenopausal women. With our com-
bined sample size, we had .80% power to detect r
2$0.025 at the
genome-wide significance threshold of 5610
–8. It is reassuring that
we were able to replicate two known associations in the sex steroid
metabolism pathway. We also identified a novel variant, which is
in relative close proximity to an estrogen receptor-related gene,
that was suggestively associated with both estradiol and testoster-
one levels. However, we were unable to detect any novel genome-
wide significant loci that influence circulating levels of estradiol,
testosterone, or SHBG.
Eight regions were identified as containing at least one SNP
associated with SHBG levels at the 10
–5 level (Table 2); the most
significant SNPs from each region together account for 11.4% of
the variance in age-adjusted log-SHBG levels. The most significant
SNPs from the 11 regions associated with estradiol explain 6.5% of
the variance in age-adjusted log-estradiol levels, and the SNPs
from the 6 regions associated with testosterone explain 4.4% of the
variance in age-adjusted log-testosterone levels (based on the SIBS
dataset). For comparison, 20%, 22% and 2% of the age-adjusted
levels of log-transformed SHBG, estradiol and testosterone
respectively were explained by BMI. Estimates of the total additive
heritability for levels of these hormones vary (e.g. [16,17]), but it is
clear that a substantial proportion of the heritability remains to be
explained. Larger genome-wide association studies may go some
way towards uncovering this missing heritability (as has been the
case for traits such as adult height and age at menarche [28,29]),
whilst rare variants that are inadequately captured by the standard
GWAS arrays may also have a role to play.
Our study replicated associations previously observed between
polymorphisms in the region of the SHBG gene with circulating
levels of SHBG. Genome-wide significance was observed for the
association with rs727428, located ,1.1 kb downstream of the
SHBG gene on chromosome 17, in both the NHS non-PMH user
GWAS (P=4.08610
–8) and SIBS GWAS (P=8.27610
–10) data
sets (joint P=2.09610
–16). Our results are consistent with prior
investigations of polymorphisms within the SHBG gene region and
circulating SHBG levels [18–21,24]. The exponentiated regression
coefficient we observed for rs727428 [T] (e
b=0.88 i.e. a 12%
reduction in convariate-adjusted SHBG levels per T allele) is very
similar to that found among postmenopausal women from the
European Prospective Investigation of Cancer-Norfolk cohort
study [18].
Sixteen additional SNPs at the SHBG locus reached genome-
wide significance in our study spanning a region of ,110 kb
comprising 11 genes, with SHBG being the most likely candidate.
However, the putative functional variant D356N (rs6259) within
SHBG, which was previously associated with 10% higher SHBG
levels among carriers [23], was not associated with SHBG levels in
our primary (joint P=0.51) or secondary meta-analysis (joint
P=0.80). Linkage disequilibrium (LD) between rs727428 and
most other SNPs at this locus is low. After adjusting analyses for
rs727428, associations with the other 16 SNPs were drastically
attenuated (joint P$0.004). Among women who did not use PMH
at blood draw, the most significant association with plasma SHBG
that remained after adjusting for rs727428 was for rs12150660
(per T allele; joint b=0.0636, joint P=0.004) indicating the
possibility of two functional variants at this locus. Rs12150660 is
strongly correlated with rs1799941, which is situated within the
SHBG proximal promoter and has previously been reported to be
associated with increased SHBG levels (r
2=0.95 in 1000 Genomes
CEU) [18,21]. Outside of the SHBG region we saw several SNPs
with suggestive evidence of association, one of which (rs12596210)
is intronic within the fat mass and obesity associated (FTO, Gene
ID: 79068) gene. As SHBG levels are known to be negatively
correlated with BMI, this may be the result of residual
confounding.
We did not obtain genome-wide significant associations with
variants for plasma estradiol levels. Among SNPs suggestively
associated with estradiol levels (P,10
–5), several SNPs at the
CYP19A1 locus were observed in our primary meta-analysis of
non-PMH users and secondary meta-analysis that included the
NHS PMH users. The CYP19A1 gene codes for aromatase, which
converts the androgens androstenedione and testosterone to
estrone and estradiol, respectively, and is the obligate enzyme
for synthesis of steroidal estrogens [30]. Rs727479 was the
CYP19A1 locus variant most significantly associated with estradiol
levels in both primary and secondary meta-analyses (joint
P=5.11610
–7 and 3.33610
–7, respectively). Our results are
consistent with prior reports on the association between
rs727479 and estradiol levels [20,25]. The suggestive CYP19A1
SNPs identified by the primary meta-analysis fall within 2
haplotype blocks toward the 39 end of the gene. After adjusting
for rs727479, associations with the remaining SNPs were
drastically attenuated. Three SNPS (rs2414095, rs12592697,
rs4775935) in perfect LD according to the HapMap database
(r
2=1.0), remained nominally associated with estradiol levels
(P,0.05). Interestingly, these SNPs are in strong LD with
rs727479 (r
2=0.96), which may indicate that they are capturing
some residual signal of an unknown causal variant imperfectly
tagged by rs727479. We were not able to replicate an association
between a SNP close to the follicle stimulating hormone receptor
(FSHR, Gene ID: 2492) gene (rs10454135) and postmenopausal
estradiol levels that was reported by a recent candidate-gene study
[20] in either the primary (P=0.55) or secondary meta-analysis
(P=0.75).
Our study did not identify variants associated with plasma
testosterone levels with genome-wide significance. One SNP
associated with suggestive significance was observed at the CYP4B1
gene locus, which is a member of the P450 family of enzymes
involved in drug and steroid hormone metabolism. We also noted
that rs10495024 was suggestively associated with both estradiol
GWAS of Estradiol, Testosterone, and SHBG
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rs10495024, an orphan nuclear receptor closely related to the
estrogen receptors (ER) capable of regulating ER target gene
expression via similar mechanisms of action [31]. While the
identification of rs10495024 by both the estradiol and testosterone
meta-analyses may indicate a genuine role of this locus in sex
steroid biosynthesis, it is also possible that the association with
testosterone levels may simply reflect the known correlation with
estradiol. In fact, all of the suggestive SNPs identified by the
primary testosterone meta-analysis may represent false positives, as
none remained associated at P,10
25 in the secondary meta-
analysis, which included the NHS PMH users. A recent GWAS
meta-analysis of over 8000 men identified variants at the SHBG
locus (rs12150660, joint P=1.2610
–41; and rs6258, joint
P=2.3610
–22) and on chromosome X at the family with sequence
similarity 9, member B (FAM9B, Gene ID: 171483) locus
(rs5934505, joint P=1.7610
–9) independently associated with
testosterone levels [24]. These variants were not associated with
circulating testosterone levels in our study of postmenopausal
women in either the primary (joint P$0.27) or secondary meta-
analysis (joint P$0.23). To our knowledge, there have not been
any convincing reports of testosterone-associated SNPs among
women.
Hormone signaling plays a central role in the etiology of breast
cancer. Estradiol, the most biologically active hormone in breast
tissue, is believed to contribute to carcinogenesis by stimulating cell
proliferation and possibly also through direct genotoxic effects of
its metabolites [32]. It is unclear whether the association of
testosterone levels and breast cancer risk reflects a direct effect
through cell proliferation or through local tissue conversion to
estrogen [33]. In epidemiologic studies, adjusting for estradiol
modestly attenuates the risk associated with high levels of
testosterone, suggesting independent effects [12]. High-affinity
binding of SHBG to estradiol and testosterone may limit their
action on target tissues. This presumably accounts for the reduced
risk of breast cancer observed in most studies among women with
the highest SHBG levels [13-15]. However, despite the proposed
role of these hormones in breast carcinogenesis, we did not find
associations between postmenopausal breast cancer risk among the
CGEMS participants and the genome-wide significant SNPs
associated with plasma SHBG or the suggestive SNPs associated
with plasma estradiol and testosterone. Our results are in line with
what was previously seen in a comprehensive assessment of
common genetic variation in known steroid metabolism genes,
including SHBG and CYP19A1, which found no significant
associations of these SNPs with breast cancer risk among 6,292
predominantly postmenopausal breast cancer cases and 8,135
controls (of which CGEMS participants were a part) [26]. Whilst
the effects of these variants on circulating levels of SHBG and
estradiol are evidently large enough to be directly detectable, it
appears that they do not change levels by a sufficient amount to
have a detectable effect on breast cancer risk. For example, each C
allele of our most significant SNP for estradiol levels (rs6016142)
was estimated to increase estradiol levels by a factor of exp
(0.
179),
which would be predicted to produce an approximately 6%
increase in breast cancer risk, based on the effects of estradiol
levels on breast cancer risk in Key et al. [13]. Therefore, it is
unlikely that, individually, other common variants that influence
plasma estradiol, testosterone, or SHBG levels among postmen-
opausal women to the same or lower extent than that identified in
our study will predict breast cancer risk.
We attempted to minimize misclassification of plasma
hormone levels by including only postmenopausal women in
our study. By definition, postmenopausal women do not
experience cyclical changes in hormone levels due to the
menstrual cycle. Hormone levels among postmenopausal women
do not appear to follow a diurnal pattern [34] and a single blood
sample was found to reflect long-term levels relatively well with
correlations of 0.68 for estradiol, 0.88 for testosterone, and 0.92
for SHBG over a period of two to three years [35]. Our primary
meta-analysis was restricted to women who were not on PMH at
blood draw to exclude potential heterogeneity in SNP effects
driven by exogenous hormone exposure. Effect estimates
observed for SNPs in the SHBG and CYP19A1 regions were
weaker in the NHS PMH user group, but supported the
association for many of those SNPs with plasma SHBG and
estradiol levels, respectively (Tables S2 and S4). This suggests
that at least some genetic variants responsible for hormone levels
are similar in the presence or absence of exogenous hormones.
By restricting our study to a single blood sample from
postmenopausal women, we were not able discover genetic
variants that regulate hormonal diurnal variation during the
prepubertal period [36], the dramatic increase in hormone levels
that occurs with puberty, the cyclical variation during the
menstrual cycle, or the major changes that occur at the
menopause, each of which could potentially contribute to breast
cancer risk later in life. Future GWAS projects in younger
females may identify novel pathways that regulate hormone levels
throughout different periods of life. Such knowledge could
potentially contribute toward developing strategies in the
prevention or treatment of this hormonally mediated disease.
Materials and Methods
Ethics Statement
All participants gave informed written consent. This study was
approved by the Committee on Use of Human Subjects of the
Brigham and Women’s Hospital, Boston, MA (NSH) as well as the
Eastern Multicentre Research Ethics Committee (SIBS).
Nurses’ Health Study Population
The Nurses’ Health Study (NHS) is a prospective cohort study
of 121,700 female registered nurses in 11 states in the United
States who were 30-55 years of age at enrollment. In 1976 and
biennially thereafter, self-administered questionnaires were used to
gather detailed information on lifestyle factors, menstrual and
reproductive factors, as well as medical history. During 1989-90,
blood samples were collected from 32,826 women forming a
subcohort from which breast cancer cases and matched controls
were selected. Eligible cases consisted of postmenopausal women
with pathologically confirmed incident invasive breast cancer
diagnosed anytime after blood collection up to June 1, 2004 with
no prior diagnosis of cancer. Controls were randomly selected
postmenopausal women free of cancer up to and including the
questionnaire cycle in which the case was diagnosed. Controls
were matched to cases according to age, blood collection variables
[time of day, season, and year of blood collection, as well as recent
(,3 months) use of postmenopausal hormones (PMH)], and
ethnicity (all cases and controls are of self-reported European
ancestry). Participants were defined as postmenopausal if they
reported having a natural menopause or bilateral oophorectomy.
Women who reported a hysterectomy with either one or both
ovaries remaining were defined as postmenopausal when they
were 56 years old (if a nonsmoker) or 54 years old (if a current
smoker), ages at which natural menopause had occurred in 90% of
the cohort. Age at menopause in the NHS is reported with a high
degree of reproducibility and accuracy [37]. Completion of the
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sample was considered to imply informed consent.
Genotyping. As part of the National Cancer Institute Cancer
Genetic Markers of Susceptibility (CGEMS) initiative 1,145
postmenopausal invasive breast cancer cases and 1,142 matched
controls selected from the Nurses’ Health Study (NHS) were
successfully genotyped using the Illumina HumanHap500 In-
finium Assay (San Diego, CA) in the first stage of a three-stage
GWAS of breast cancer susceptibility. Quality control metrics
included removal of samples with call rates under 90% and SNP
assays with call rates under 95%. Single nucleotide polymorphisms
(SNP) with a minor allele frequency (MAF) of ,1% were removed
for a total of 528,252 genotyped SNPs [38]. Of the participants
included in the CGEMS initiative, 851 cases and 852 controls had
estradiol, testosterone, and/or SHBG levels measured. Principal
components of genetic variation were calculated with EIGEN-
STRAT software [39] as described by Hunter et al., 2007 [38].
Hormone measurements. Details of the laboratory meth-
ods used to measure hormone levels among NHS participants are
described elsewhere [40,41]. Briefly, plasma levels of each
hormone were assayed in up to 8 batches. The first 7 batches of
estradiol and testosterone were measured at the Quest Diagnostics’
Nichols Institute (San Juan Capistrano, CA) using radioimmuno-
assay, after organic extraction and celite column chromatography.
The 8
th batch of estradiol and testosterone was measured at the
Mayo Clinic (Rochester, MN) using liquid chromatography-
tandem mass spectrometry (ThermoFisher Scientific, Franklin,
MA and Applied Biosystems-MDS Sciex, Foster City, CA). For
SHBG, the first two batches were assayed at the University of
Massachusetts Medical Center’s Longcope Steroid Radioimmu-
noassay Laboratory (Worchester, MA) using an immunoradio-
metric kit from FARMOS Diagnostica (Orion, Corp., Turku,
Finland). All subsequent batches were assayed at the Reproductive
Endocrinology Unit Laboratory at Massachusettes General
Hospital (Boston, MA) using the AxSYM Immunoassay System
(Abbott Diagnostics).
The detection limits of the radioimmunoassays were as follows:
2 pg/ml for estradiol, 2 ng/dl for testosterone, and 6.25 nmol/L
for SHBG. When plasma hormone values were reported as less
than the detection limit, we set the value to one unit less than the
limit (estradiol, n=8; testosterone, n=10). Hormone values were
log transformed to improve normality. Batch-specific outliers were
identified using an extreme studentized deviate many-outlier
procedure [42] and excluded from analyses. We included 10%
blinded replicates in each batch to assess laboratory precision.
Mean coefficients of variation (CV) were 13.9% for estradiol
(range: 4.1% to 27.6%), 12.5% for testosterone (range: 6.6% to
13.9%), and 12.2% for SHBG (range: 9.3% to 21.9%).
Sisters in Breast Screening Study Population
The Sisters in Breast Screening study (SIBS) was initially
designed to map genes associated with mammographic breast
density. Families were identified through the National Health
Service breast screening program in the United Kingdom.
Eligibility was restricted to families in which two or more female
blood relatives (sisters, half sisters, first cousins, or aunt-niece) had
had mammographic screening. Families whose second member
could have screening within two years of the first member’s
recruitment were also included. Study participants were sent a
letter, blood kit, and questionnaire covering information on family
information, reproductive and menstrual history, oral contracep-
tive use, PMH use, life-style factors, and medical history including
benign breast disease and cancer history. Current height and
weight were measured at general practices, and blood samples
were collected by practice nurses or phlebotomists. Recruitment
occurred between 2002 and 2010.
Genotyping. As part of an ongoing genome-wide study, 1302
SIBS women were genotyped using the Illumina HumanCy-
toSNP-12 platform. SNP assays with call rates ,95%, SNPs with a
MAF of ,1%, or Hardy-Weinberg Equilibrium P,10
-4 were
removed for a total of 255,051 genotyped SNPs. The call rate was
.99% for all samples. Six women were excluded due to less than
90% estimated European ancestry. For 9 pairs of monozygotic
twins (confirmed by genotyping), the twin with the lower call rate
was excluded.
Hormone measurements. A subset of 905 SIBS women
who were aged over 55 years at recruitment, two or more years
since their last menstrual period, and not currently using PMH at
the time of blood collection were selected for hormone
measurement at The Royal Marsden Hospital (London, UK),
of whom 819 were also included in the GWAS (after exclusions
described above). The women were from 390 separate families.
Plasma estradiol concentrations were measured using an in-house
radio-immunoassay (RIA) using a highly specific rabbit antiserum
which had been raised against an estradiol-6-carboxymethylox-
ime-bovine serum albumin conjugate and estradiol-6-carboxy-
methyloxime-[2-
125I] iodohistamine [43]. SHBG was measured
using Immulite chemiluminescent immunoassay. Plasma testos-
terone levels were measured using RIA kit from DPC (Seimens).
Estradiol measurements greater than 300 pmol/L were excluded
(n=12). The detection limits were 3 pmol/L for estradiol
(n=29/902) and 0.14 nmol/L for testosterone (n=34/905), and
values were replaced with these limits when they were reported
as being undetectable. For estradiol at a concentration of 25
pmol/l the within assay variation was 6.5% and the between
assay variation was 16% (n=18). For testosterone, at a
concentration of 2.5nmol/l, the within assay variation was 7%
and the between assay variation was 16% (n=28). For SHBG at
a concentration of 50 nmol/l the within assay variation was 5.8%
and the between assay variation was 6.6% (n=7).
Statistical Analyses
Genotypes for more than 2.5 million SNPs were imputed
separately for the NHS and SIBS studies using MACH software
[44,45] (r
2.0.80) and data from the HapMap European CEU
panel as a reference (Phase II, release 21). Exported counts of
minor allele SNP ‘‘dosages’’ were used in subsequent association
analyses.
Among the NHS participants, association analyses were
stratified by recency of PMH use at blood draw to allow for
discordant associations between the two groups. The ‘‘PMH
user’’ group consisted of women who used PMH within 3
months of blood collection, whereas the ‘‘non-PMH user’’ group
consisted of women who had never used PMH and women who
had stopped PMH use more than 3 months prior to blood
collection.
The NHS and SIBS studies were both analyzed using log
transformed hormone levels and each SNP’s imputed genetic
dosages. Although the two studies had treated hormone values
below the level of detection differently (setting to the minimum
detectable value in the SIBS study and to one unit less than the
detectable value in the NHS study) this affected only a very small
number of participants. Additive models with 1 degree of
freedom were implemented in the ProbABEL software package
[46]. All analyses were adjusted for age at blood collection
(continuous), body mass index (BMI, continuous; kg/m
2),
laboratory batch and previous PMH use (yes/no) (except among
the NHS ‘‘PMH user’’ group). Testosterone analyses were
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bilateral oophorectomy (yes/no) at the time of blood collection.
The SIBS SHBG analysis was also adjusted for waist:hip ratio.
NHS linear regression analyses were also adjusted for disease
status, and the top principal components of genetic variation
chosen after excluding any admixed individuals clearly not of
European descent. Given the family-based design of the SIBS
study, we used the matrix of kinship coefficients between all pairs
of individuals (estimated using 8236 uncorrelated SNPs) to adjust
for the non-independence of relatives in a score test for the
association between SNPs and a quantitative trait. This approach
is also expected to avoid the effects of population stratification in
most situations [47].
Primary meta-analyses were conducted between the NHS non-
PMH user group and the SIBS study participants, all of whom
were non-PMH users at blood draw. Meta-analyses were based
on summary statistics from the two studies including a total of
1583 women of European ancestry for the estradiol analysis,
1589 women for the testosterone analysis, and 1598 for the
SHBG analysis. Secondary meta-analyses included the NHS
PMH user group, which added an additional 668, 875, and 898
participants to the estradiol, testosterone, and SHBG meta-
analyses, respectively (Table 1). For each SNP, we calculated
combined effect estimates based on study-specific effect sizes and
standard errors using METAL software [48]. Heterogeneity
estimates were calculated using Cochran’s Q and I2 statistics.
Power calculations were performed using QUANTO [49].
Supporting Information
Figure S1 Log Quantile-Quantile P-value plot of plasma SHBG
levels. The observed –log10 P-values (Y-axis) of 2,586,346 SNPs
from a meta-analysis of NHS non-PMH users and SIB study
participants (individual analyses adjusted as described in the
Materials and Methods section) for plasma SHBG levels plotted
against the expected –log10 quantile (X-axis) under the null
distribution. The dashed line represents imputed P values.
(PNG)
Figure S2 Log Quantile-Quantile P-value plot of plasma
Estradiol levels. The observed –log10 P-values (Y-axis) of
2,586,232 SNPs from a meta-analysis of NHS non-PMH users
and SIB study participants (individual analyses adjusted as
described in the Materials and Methods section) for plasma
estradiol levels plotted against the expected –log10 quantile (X-
axis) under the null distribution. The dashed line represents
imputed P values.
(PNG)
Figure S3 Log Quantile-Quantile P-value plot of plasma
Testosterone levels. The observed –log10 P-values (Y-axis) of
2,586,346 SNPs from a meta-analysis of NHS non-PMH users and
SIB study participants (individual analyses adjusted as described in
the Materials and Methods section) for plasma testosterone levels
plotted against the expected –log10 quantile (X-axis) under the
null distribution. The dashed line represents imputed P values.
(PNG)
Figure S4 Manhattan plot of plasma SHBG levels. The –log10
P-values from the meta-analysis of NHS non-PMH users and SIBS
study participants (individual analyses adjusted as described in the
Materials and Methods section) for plasma SHBG levels plotted
against chromosomal base-pair position. The chromosomes are
color coded.
(PNG)
Figure S5 Manhattan plot of plasma Estradiol levels. The –
log10 P-values from the meta-analysis of NHS non-PMH users
and SIBS study participants (individual analyses adjusted as
described in the Materials and Methods section) for plasma
estradiol levels plotted against chromosomal base-pair position.
The chromosomes are color coded.
(PNG)
Figure S6 Manhattan plot of plasma Testosterone levels. The –
log10 P-values from the meta-analysis of NHS non-PMH users
and SIBS study participants (individual analyses adjusted as
described in the Materials and Methods section) for plasma
testosterone levels plotted against chromosomal base-pair position.
The chromosomes are color coded.
(PNG)
Table S1 SNPs associated with log SHBG levels at P,10
25
from a meta-analysis of the NHS GWAS and SIBS study GWAS
among non-PMH users
(PDF)
Table S2 SNPs associated with log SHBG levels at P,10
25
from a meta-analysis of NHS GWAS (non-PMH and PMH users)
and SIBS study GWAS
(PDF)
Table S3 SNPs associated with log E2 levels at P,10
25 from a
meta-analysis of the NHS GWAS and SIBS study GWAS among
non-PMH users
(PDF)
Table S4 SNPs associated with log E2 levels at P,10
25 from a
meta-analysis of NHS GWAS (non-PMH and PMH users) and
SIBS study GWAS
(PDF)
Table S5 SNPs associated with log T levels at P,10
25 from a
meta-analysis of the NHS GWAS and SIBS study GWAS among
non-PMH users
(PDF)
Table S6 SNPs associated with log T levels at P,10
25 from a
meta-analysis of NHS GWAS (non-PMH and PMH users) and
SIBS study GWAS
(PDF)
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